Status
Conditions
Treatments
About
In recent years, knowledge of neuromuscular diseases has advanced considerably, and new therapeutic avenues are beginning to emerge. The proliferation of clinical trials has created a need to identify biomarkers that are both sensitive to changes and specific to the disease. Current gait tests only consider the time factor and not the evolution of the patient's biomechanics, which may prove insufficient for patients whose symptoms generally progress slowly. Quantifying gait parameters in neuromuscular patients therefore appears necessary. This is why we propose to study markerless gait analysis in this population, which would allow for simple and effective monitoring of kinematic parameters without resorting to complex equipment incompatible with routine clinical practice.
Enrollment
Sex
Ages
Volunteers
Inclusion and exclusion criteria
All volunteers
Volunteers with a neuromuscular disease
Exclusion Criteria
All volunteers
Asymptomatic volunteers
Volunteers with a neuromuscular disease
Exclusion criteria
Primary purpose
Allocation
Interventional model
Masking
30 participants in 1 patient group
Loading...
Central trial contact
Romain FEIGEAN, PhD; Pauline SANTMARTY, MsC
Data sourced from clinicaltrials.gov
Clinical trials
Research sites
Resources
Legal